drugset / Trial / NCT07399951

Washington University WU 409: Immune Responses to Rabies Vaccine.

NCT07399951

Phase 0 Completed 31 enrolled Washington University School of Medicine
RandomizedSingle-groupOpen-labelBasic science

Summary

This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of Imovax® or RabAvert® seven days apart with no RIG); 2) rabies pre-exposure prophylaxis regimen + day 0 RIG (two doses of Imovax® or RabAvert® seven days apart, with RIG administered at day 0); 3) rabies pre-exposure prophylaxis regimen + day 28 RIG (two doses of Imovax® or RabAvert® seven days apart, with RIG administered at day 28).

Timeline

Start
2023-10-19
Primary completion
2025-06-24
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HyperRAB Unknown
Subject Imovax Vaccine
Subject Rabies vaccine Vaccine

Indications

No indication recorded.